Amneal Pharmaceuticals, Inc. (AMRX)
NASDAQ: AMRX · Real-Time Price · USD
12.74
+0.17 (1.35%)
At close: Apr 28, 2026, 4:00 PM EDT
12.74
-0.01 (-0.04%)
After-hours: Apr 28, 2026, 4:01 PM EDT
Amneal Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 3,019 | 2,794 | 2,394 | 2,212 | 2,094 | Upgrade
|
| Revenue Growth (YoY) | 8.05% | 16.73% | 8.20% | 5.67% | 5.08% | Upgrade
|
| Cost of Revenue | 1,890 | 1,778 | 1,541 | 1,421 | 1,310 | Upgrade
|
| Gross Profit | 1,128 | 1,016 | 852.87 | 791.46 | 783.95 | Upgrade
|
| Selling, General & Admin | 526.85 | 476.54 | 429.78 | 399.7 | 365.5 | Upgrade
|
| Research & Development | 186.15 | 190.61 | 163.85 | 195.69 | 201.85 | Upgrade
|
| Other Operating Expenses | -5.24 | - | -1.14 | -3.96 | - | Upgrade
|
| Operating Expenses | 707.76 | 667.15 | 592.49 | 591.43 | 567.35 | Upgrade
|
| Operating Income | 420.7 | 348.36 | 260.38 | 200.03 | 216.6 | Upgrade
|
| Interest Expense | -241.09 | -258.6 | -210.63 | -158.38 | -136.33 | Upgrade
|
| Currency Exchange Gain (Loss) | 7.64 | -6.85 | 1.67 | -12.36 | -0.36 | Upgrade
|
| Other Non Operating Income (Expenses) | 9.93 | -42.66 | 5.12 | 17.83 | 15.33 | Upgrade
|
| EBT Excluding Unusual Items | 197.18 | 40.26 | 56.54 | 47.13 | 95.25 | Upgrade
|
| Merger & Restructuring Charges | -4.21 | -2.36 | -1.75 | -2.13 | -9.91 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 3.76 | - | - | - | Upgrade
|
| Asset Writedown | -22.78 | -0.92 | -36.13 | -11.11 | -22.69 | Upgrade
|
| Legal Settlements | 0.39 | -96.69 | -1.82 | -269.93 | -25 | Upgrade
|
| Other Unusual Items | -31.37 | 0.93 | -26.31 | -1.02 | -10.57 | Upgrade
|
| Pretax Income | 139.21 | -55.01 | -40.27 | -248.13 | 31.37 | Upgrade
|
| Income Tax Expense | 11.28 | 18.86 | 8.45 | 6.66 | 11.2 | Upgrade
|
| Earnings From Continuing Operations | 127.93 | -73.88 | -48.72 | -254.79 | 20.17 | Upgrade
|
| Minority Interest in Earnings | -55.88 | -43.01 | -35.27 | 124.8 | -9.55 | Upgrade
|
| Net Income | 72.06 | -116.89 | -83.99 | -129.99 | 10.62 | Upgrade
|
| Net Income to Common | 72.06 | -116.89 | -83.99 | -129.99 | 10.62 | Upgrade
|
| Net Income Growth | - | - | - | - | -88.33% | Upgrade
|
| Shares Outstanding (Basic) | 313 | 309 | 176 | 151 | 149 | Upgrade
|
| Shares Outstanding (Diluted) | 325 | 309 | 176 | 151 | 152 | Upgrade
|
| Shares Change (YoY) | 5.12% | 75.42% | 16.69% | -0.58% | 1.95% | Upgrade
|
| EPS (Basic) | 0.23 | -0.38 | -0.48 | -0.86 | 0.07 | Upgrade
|
| EPS (Diluted) | 0.22 | -0.38 | -0.48 | -0.86 | 0.07 | Upgrade
|
| EPS Growth | - | - | - | - | -88.52% | Upgrade
|
| Free Cash Flow | 241.15 | 234.76 | 298.78 | 16.3 | 190.88 | Upgrade
|
| Free Cash Flow Per Share | 0.74 | 0.76 | 1.70 | 0.11 | 1.26 | Upgrade
|
| Gross Margin | 37.38% | 36.35% | 35.63% | 35.77% | 37.44% | Upgrade
|
| Operating Margin | 13.94% | 12.47% | 10.88% | 9.04% | 10.35% | Upgrade
|
| Profit Margin | 2.39% | -4.18% | -3.51% | -5.88% | 0.51% | Upgrade
|
| Free Cash Flow Margin | 7.99% | 8.40% | 12.48% | 0.74% | 9.12% | Upgrade
|
| EBITDA | 644.27 | 584.55 | 489.78 | 440.21 | 450 | Upgrade
|
| EBITDA Margin | 21.34% | 20.92% | 20.46% | 19.90% | 21.49% | Upgrade
|
| D&A For EBITDA | 223.57 | 236.19 | 229.4 | 240.18 | 233.41 | Upgrade
|
| EBIT | 420.7 | 348.36 | 260.38 | 200.03 | 216.6 | Upgrade
|
| EBIT Margin | 13.94% | 12.47% | 10.88% | 9.04% | 10.35% | Upgrade
|
| Effective Tax Rate | 8.10% | - | - | - | 35.70% | Upgrade
|
| Advertising Expenses | 42 | 34.4 | 12.4 | 16.8 | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.